One-hundred and eighteen of 451 patients (26.2%) were HIV positive, with a median CD4 count of 179 (interquartile range (IQR): 91, 279), and 63.9% were in WHO clinical stage 3 at the commencement of MDR-TB treatment. Here, CD4 is linked to tuberculosis.